secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLx Pharma Winddown Corp. (—)
CIK:        0001497504
Form:       8-K
Filed at:   2023-02-13T23:59:59+00:00
Accession:  0001193805-23-000207
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PLx Pharma gets Nasdaq audit committee deficiency; chairman exits exec role; retention plan for CEO/CFO approved
--------------------------------------------------------------------------------

- Nasdaq gave PLx Pharma until Jan 19, 2024 (or July 18, 2023 if annual meeting sooner) to add third independent director to audit committee after Hadden exit.
- Executive Chairman Valentino to cease as executive Feb 14; receives $91,875 severance, stays on board as non-executive chairman.
- Retention plan: CEO Giordano $610k, CFO O'Connor $511.5k paid up-front; repay if leave for cause or voluntarily before Aug 31, 2023.
- Company reviewing strategic alternatives including possible liquidation; retention plan meant to retain key executives during restructuring.
- Retention awards cancel existing severance obligations in CEO and CFO employment agreements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1497504/000119380523000207/0001193805-23-000207-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1497504/000119380523000207/e618271_8k-plx.htm
  HTML page:      https://secwatch.observer/filing/0001193805-23-000207

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer